MX2009005550A - Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. - Google Patents

Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.

Info

Publication number
MX2009005550A
MX2009005550A MX2009005550A MX2009005550A MX2009005550A MX 2009005550 A MX2009005550 A MX 2009005550A MX 2009005550 A MX2009005550 A MX 2009005550A MX 2009005550 A MX2009005550 A MX 2009005550A MX 2009005550 A MX2009005550 A MX 2009005550A
Authority
MX
Mexico
Prior art keywords
promotion
cardiac hypertrophy
inhibitors
protein tyrosine
tyrosine phosphatase
Prior art date
Application number
MX2009005550A
Other languages
English (en)
Inventor
Jey Raju Jeyaseelan
Mie Abe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005550A publication Critical patent/MX2009005550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refieri al uso de inhibidores de fosfatasa de proteína tirosina para la promoción de hipertrofia cardíaca fisiológica y el tratamiento de la hipertrofia cardíaca patológica.
MX2009005550A 2006-12-01 2007-11-30 Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica. MX2009005550A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87232606P 2006-12-01 2006-12-01
PCT/US2007/086070 WO2008070552A2 (en) 2006-12-01 2007-11-30 Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy

Publications (1)

Publication Number Publication Date
MX2009005550A true MX2009005550A (es) 2009-06-05

Family

ID=39232939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005550A MX2009005550A (es) 2006-12-01 2007-11-30 Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.

Country Status (10)

Country Link
US (1) US20100035860A1 (es)
EP (1) EP2089026A2 (es)
JP (1) JP2010511629A (es)
KR (1) KR20090087019A (es)
CN (1) CN101547694A (es)
AU (1) AU2007329512A1 (es)
BR (1) BRPI0719359A2 (es)
CA (1) CA2670491A1 (es)
MX (1) MX2009005550A (es)
WO (1) WO2008070552A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067613A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
CN101321743A (zh) * 2005-12-08 2008-12-10 诺瓦提斯公司 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途
AU2016270903B2 (en) 2015-06-03 2020-04-30 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists for use in the treatment of cardiovascular disorders
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237463A (en) * 1990-03-23 1993-07-27 Merck & Co Inc Protein phosphatase inhibitor-1 (ppi-1), dna encoding it, vectors and host cells
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CA2670491A1 (en) 2008-06-12
CN101547694A (zh) 2009-09-30
WO2008070552A2 (en) 2008-06-12
KR20090087019A (ko) 2009-08-14
US20100035860A1 (en) 2010-02-11
JP2010511629A (ja) 2010-04-15
AU2007329512A1 (en) 2008-06-12
EP2089026A2 (en) 2009-08-19
BRPI0719359A2 (pt) 2014-10-07
WO2008070552A3 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
DK3323815T3 (en) Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use
IL196129A0 (en) Human protein tyrosine phosphatase inhibitors and methods of use
ZA200900558B (en) Human protein tyrosine phosphatase inhibitors and methods of use
MX2010005909A (es) Combinacion de inhibidores de fosfatasa de proteina tirosina y hormona de crecimiento humana para el tratamiento de atrofia muscular y trastornos relacionados.
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
PH12014500053A1 (en) Proteasome inhibitors
NO20092637L (no) Fremgangsmater for behandling
UA94221C2 (en) Lipocalin protein
MA32372B1 (fr) INHIBITEURS DPP-IV à UTILISER DANS LE TRAITEMENT DE LA NAFLD
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
ATE410235T1 (de) Behandlung von ballastwasser
EP2294197A4 (en) HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
ZA200900492B (en) Human protein tyrosine phosphatase inhibitors and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal